Skip to main content

Advertisement

Table 1 Unadjusted outcomes at 3 years of acute myeloid leukemia (AML) patients with t(8;21) who achieved complete remission after 1–2 induction chemotherapy cycles

From: Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation

Group CIR rate LFS rate OS rate
Chemotherapy only 71% (63%–80%) 26% (15%–43%) 41% (25%–58%)
Auto-HSCT 8% (0%–71%) 85% (51%–96%) 92% (57%–99%)
Allo-HSCT 16% (10%–22%) 72% (56%–83%) 77% (61%–87%)
All cohorts 37% (25%–50%) 56% (45%–65%) 65% (54%–74%)
  1. CIR cumulative incidence of relapse, LFS leukemia-free survival, OS overall survival, allo-HSCT allogeneic hematopoietic stem cell transplantation, auto-HSCT autologous-hematopoietic stem cell transplantation